Your clinical trial enrollment is lagging behind —here's how to speed it back up https://t.co/aa363lLkkn

https://t.co/3c7iLyShj8

Why do psychedelics work where other treatments falter? Conventional treatments tweak serotonin levels like turning a dial on a radio – helpful, but static. Psychedelics flood the brain with neuroplasticity. They disrupt echo chambers of rumination, boost BDNF for new neural

Reflecting on the Psychedelic Revolution After an incredible journey at Cybin, I'm more passionate than ever about the seismic shift happening in neuropsychiatry. For over 30 years in healthcare, I've seen the limitations of traditional treatments for mental health – low

Space tryp? https://t.co/t6mFcYhvIp

Excited to have my friend Daniel Carcillo @CarBombBoom13 join the BetterLife $BETRF team. His passion for helping post concussion and TBI survivors is truly inspiring. “Joining BetterLife feels like the natural next step in my mission to help concussion survivors because we are

Sitting minutes away from the Bunker Hill Monument this Thanksgiving week reading about Sarah Josepha Hale. She didn’t just raise the cash to get the monument completed, she invented modern Thanksgiving, bullied 5 presidents for 36 years until Lincoln caved, and single-handedly

It's often said that the stock market is not the economy. But the two seem particularly far apart lately. - S&P 500 up ~12% year to date - Nasdaq up 15% - AI stocks surging: Nvidia (+28%), Meta (+27%) , Microsoft (+22%), Palantir (+126%), Oracle (+80%) BUT: - Consumer

Mark Cuban (@mcuban) does a great job explaining how middlemen pharmacy benefit managers (PBMs) drive up the cost of prescription drugs for Americans, thus setting up the need for Congress to pass reforms Cuban: The US has the highest drug prices in the world "because we are the

Exciting News in Mental Health Innovation: ARPA-H Announces $100M EVIDENT Initiative! Thrilled to share that the Advanced Research Projects Agency for Health (ARPA-H) is stepping up with a game-changing $100 million investment to revolutionize behavioral health treatments. Their

International Men's Day, is an opportunity to shine a light on the persistent challenges surrounding men's mental health. Even in 2025, men worldwide are grappling with a serious mental health crisis, with men accounting for about 78% of all suicide deaths in the US. Deep-rooted

Psychedelic Bulletin 214: - Largest LSD Microdosing Trial Fails Across All Endpoints - AtaiBeckley’s Phase 2b Debrief - UK Gov. Holds Line on Psilocybin Despite MPs' Written Questions - MAHA Summit ft. Psychedelics - VA's Ph 3 Psilocybin Study https://t.co/QE45HyJ3BC

Quote of the day. #qotd

❔❔❔Question for the biotech hive. Which are the best CNS focused CROs for a Phase 2 proof of concept study? Why would you recommend them? Looking to create a go-to list for the CNS community. TIA

NPLB’s recent letter to FDA Commissioner Makary, informed by insights gathered in a survey of biotech execs. The Importance of a Strong and Predictable FDA @NPLB_org https://t.co/GDGTuRaRM6

Why making Richard Pazdur CDER head is good for patients, pharma My take! Featuring a pic of ⁦@adamfeuerstein⁩.

On this Veterans Day, let’s honor the brave men and women who’ve served our nation with unwavering courage and sacrifice. Your dedication keeps us safe and free. Thank you for your service! 🇺🇸 #VeteransDay

I am excited to be moderating a panel of incredible speakers from across the psychedelic medicine sector, entitled The Future of Psychedelic Medicine in America: Science, Safety & Scale. Join me, along with Jonathan Sporn, CEO & Chairman, @GilgameshRX Teri Loxam, CFO

I am delighted to be supporting BETR-001 for cluster headache, migraine, and pain - BetterLife's $BETR patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD. Previous forms of 2-bromo-LSD have been shown to be non-hallucinogenic, safe and tolerable in

Drug spending isn't the driver of increasing healthcare costs in any OECD country. Drug spend grew slowly for 25 years (yellow line), while overall healthcare spending outpaces it (blue line). New IQVIA report: https://t.co/eCbEGdVBfe